The National Medicines Regulatory Authority hereby informs all medicine importers and local manufacturers in Sri Lanka that registration applications are accepted for the extended release formulations of Methylphenidate, Lisdexamfetamine and other related stimulant medicines used in the management of Attention Deficit Hyperactivity Disorder (ADHD).

‍

‍